About: Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection
Creator	Dhama, Kuldeep Tiwari, Ruchi Go, Evum Sansthan, Anusandhan Keam, Synat Kumar, Shailesh Harapan, \| Megawati, \|
Source	Medline; PMC
abstract	The outbreak of coronavirus disease 2019 (COVID‐19) and pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has become a major concern globally. As of 14 April 2020, more than 1.9 million COVID‐19 cases have been reported in 185 countries. Some patients with COVID‐19 develop severe clinical manifestations, while others show mild symptoms, suggesting that dysregulation of the host immune response contributes to disease progression and severity. In this review, we have summarized and discussed recent immunological studies focusing on the response of the host immune system and the immunopathology of SARS‐CoV‐2 infection as well as immunotherapeutic strategies for COVID‐19. Immune evasion by SARS‐CoV‐2, functional exhaustion of lymphocytes, and cytokine storm have been discussed as part of immunopathology mechanisms in SARS‐CoV‐2 infection. Some potential immunotherapeutic strategies to control the progression of COVID‐19, such as passive antibody therapy and use of interferon αβ and IL‐6 receptor (IL‐6R) inhibitor, have also been discussed. This may help us to understand the immune status of patients with COVID‐19, particularly those with severe clinical presentation, and form a basis for further immunotherapeutic investigations.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1002/rmv.2123
bibo:pmid	32648313
has license	no-cc
sha1sum (hex)	687cff5e2c1813cefb86dff9b5c891776292191f
schema:url	https://doi.org/10.1002/rmv.2123
resource representing a document's title	Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection
has PubMed Central identifier	PMC7404843
has PubMed identifier	32648313
schema:publication	Rev Med Virol
resource representing a document's body	covid:687cff5e2c1813cefb86dff9b5c891776292191f#body_text
is schema:about of	named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'membrane fusion' named entity '229E' named entity 'NS4b' named entity 'macrophages' named entity 'infection' named entity 'SARS-CoV' named entity 'IFN' named entity 'COVID' named entity 'CD4' named entity 'lungs' named entity 'COVID-19' named entity 'protein' named entity 'COVID' named entity 'IL-6 receptor' named entity 'antigen' named entity 'epithelial cells' named entity 'receptor expression' named entity 'pneumonia' named entity 'hydrophobic' named entity 'IFN' named entity 'CD4' named entity 'IFN' named entity 'infection' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'liver' named entity 'COVID-19' named entity 'immunotherapy' named entity 'COVID' named entity 'Cytotoxic T cells' named entity 'rheumatoid arthritis' named entity 'lymphocytes' named entity 'IFN-γ' named entity 'epitopes' named entity 'antibodies' named entity 'virus' named entity 'lungs' named entity 'COVID-19 pandemic' named entity 'tocilizumab' named entity 'SARS-CoV-2' named entity 'innate immune responses' named entity 'CD8 +' named entity 'protein synthesis' named entity 'respiratory failure' named entity 'IFN' named entity 'cytokine storm syndrome' named entity 'immune cells' named entity 'granzyme' named entity 'interferon' named entity 'tocilizumab' named entity 'SARS-CoV-2' named entity 'CD107a' named entity 'programmed death receptor' named entity 'antiviral' named entity 'COVID' named entity 'IgM' named entity 'IL-6 receptor' named entity 'macrophages' named entity 'SARS-CoV-2' named entity 'IFN' named entity 'IL-6 receptor' named entity 'NK cells' named entity 'IL-1β' named entity 'IFN' named entity 'SARS-CoV-2' named entity 'lymphocytes' named entity 'lyse' named entity 'ADCC' named entity 'pathogenesis' named entity 'Helper T cells' named entity 'IgM' named entity 'nucleoprotein' named entity 'viral titer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software